Andreas Halvorsen: portfolio of Viking Global Investors

Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.

Source: 13F filing with the US Securities and Exchange Commission dated May 15, 2024. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q1 2024. Go to the latest filing (Q3 2026)

26.9B USDQ1 2024
Total value of stock positions
26.9B USD
Positions
83
Share of the ten largest
40.9%

The ten largest positions Q1 2024

  1. Visa Inc. 6.6%▲ +11.2%
  2. Workday, Inc. 5.4%▲ +28.8%
  3. Amazon 4.6%▲ +40.0%
  4. Philip Morris International 4.4%▲ +35.3%
  5. Api Group Corp 4.2%▼ −15.5%
  6. U.S. Bancorp 3.8%▲ +136.4%
  7. Las Vegas Sands 3.3%new
  8. Fortive 3.0%▼ −9.8%
  9. Bridgebio Pharma Inc 2.9%unchanged
  10. Roivant Sciences Ltd 2.7%unchanged
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 38.5B USD).
Choose a quarter (54 filings)

All positions Q1 2024

Positions Q1 2024 per 13F filing, 50 of 83
Symbol Weight Shares Reported value Change Held since
AMZN Amazon 4.6% 6,902,351 1.2B USD +40.0% increased Q2 2015 36 quarters
V Visa Inc. 6.6% 6,327,962 1.8B USD +11.2% increased Q3 2016 31 quarters
Bridgebio Pharma Inc 2.9% 25,120,991 776.7M USD unchanged Q2 2019 20 quarters
Adaptive Biotechnologies Cor 0.4% 29,993,708 96.3M USD unchanged Q2 2019 20 quarters
FTV Fortive 3.0% 9,497,292 817.0M USD −9.8% reduced Q3 2019 19 quarters
Api Group Corp 4.2% 28,984,298 1.1B USD −15.5% reduced Q2 2020 16 quarters
Royalty Pharma PLC 1.3% 11,485,547 348.8M USD +13.9% increased Q2 2020 16 quarters
TMO Thermo Fisher Scientific 0.3% 128,489 74.7M USD −76.1% reduced Q2 2020 16 quarters
Inhibrx Inc 0.9% 7,150,826 250.0M USD unchanged Q3 2020 15 quarters
GE GE Aerospace 1.8% 2,731,787 479.5M USD −46.3% reduced Q4 2020 14 quarters
META Meta Platforms 1.3% 731,983 355.4M USD −75.5% reduced Q4 2020 14 quarters
Acadia Healthcare Company In 0.8% 2,564,237 203.1M USD −8.4% reduced Q4 2020 14 quarters
4D Molecular Therapeutics In 0.3% 2,934,914 93.5M USD −38.7% reduced Q4 2020 14 quarters
Kinnate Biopharma Inc < 0.1% 1,820,462 4.8M USD unchanged Q4 2020 14 quarters
AMP Ameriprise Financial 2.7% 1,626,845 713.3M USD −15.0% reduced Q1 2021 13 quarters
Pharvaris N V 0.3% 3,653,310 84.4M USD −0.1% reduced Q1 2021 13 quarters
Edgewise Therapeutics Inc 0.2% 3,339,146 60.9M USD – Q1 2021 13 quarters
Zai Lab Ltd 0.1% 2,048,129 32.8M USD +9.6% increased Q1 2021 13 quarters
Day One Biopharmaceuticals I 0.2% 2,558,563 42.3M USD unchanged Q2 2021 12 quarters
Hdfc Bank Ltd 1.2% 5,929,295 331.9M USD −39.1% reduced Q3 2021 11 quarters
Ginkgo Bioworks Holdings Inc 0.6% 143,085,126 166.0M USD unchanged Q3 2021 11 quarters
Rallybio Corp < 0.1% 4,194,777 7.8M USD unchanged Q3 2021 11 quarters
Roivant Sciences Ltd 2.7% 69,368,961 731.1M USD unchanged Q4 2021 10 quarters
Biomarin Pharmaceutical Inc 2.1% 6,416,288 560.4M USD +31.2% increased Q4 2021 10 quarters
PGR Progressive Corporation 2.3% 3,032,941 627.3M USD −48.3% reduced Q1 2022 9 quarters
MA Mastercard 1.4% 794,313 382.5M USD −31.4% reduced Q1 2022 9 quarters
MCK McKesson Corporation 1.2% 590,580 317.1M USD −73.6% reduced Q2 2022 8 quarters
Pepgen Inc < 0.1% 1,482,434 21.8M USD unchanged Q2 2022 8 quarters
UNH UnitedHealth Group 2.5% 1,361,207 673.4M USD +195.4% increased Q3 2022 7 quarters
Valvoline Inc 0.4% 2,383,579 106.2M USD −25.0% reduced Q3 2022 7 quarters
Trevi Therapeutics Inc < 0.1% 4,400,000 15.2M USD unchanged Q3 2022 7 quarters
Newamsterdam Pharma Company 0.7% 8,024,565 189.8M USD unchanged Q4 2022 6 quarters
CSX CSX Corporation 0.5% 3,957,797 146.7M USD +26.3% increased Q4 2022 6 quarters
WDAY Workday, Inc. 5.4% 5,288,586 1.4B USD +28.8% increased Q1 2023 5 quarters
Cnh Indl N V 0.6% 11,956,128 155.0M USD +21.3% increased Q1 2023 5 quarters
Viking Therapeutics Inc 0.3% 1,094,940 89.8M USD – Q1 2023 5 quarters
PM Philip Morris International 4.4% 13,016,896 1.2B USD +35.3% increased Q2 2023 4 quarters
DHR Danaher Corporation 2.6% 2,837,937 708.7M USD −29.1% reduced Q2 2023 4 quarters
CBRE CBRE Group 1.7% 4,568,632 444.3M USD +19.9% increased Q2 2023 4 quarters
FIVE9 Inc 0.8% 3,452,138 214.4M USD +27.2% increased Q2 2023 4 quarters
Epam Sys Inc 0.6% 579,543 160.0M USD +57.2% increased Q2 2023 4 quarters
PPG PPG Industries 0.3% 619,433 89.8M USD −36.1% reduced Q2 2023 4 quarters
Verastem Inc 0.1% 2,456,292 29.0M USD unchanged Q2 2023 4 quarters
FCX Freeport-McMoRan 1.7% 9,517,164 447.5M USD −13.9% reduced Q3 2023 3 quarters
ISRG Intuitive Surgical 1.1% 771,837 308.0M USD −17.1% reduced Q3 2023 3 quarters
KDP Keurig Dr Pepper 0.5% 4,461,076 136.8M USD +54.5% increased Q3 2023 3 quarters
BSX Boston Scientific 0.4% 1,724,755 118.1M USD −23.9% reduced Q3 2023 3 quarters
BEKE KE Holdings 0.3% 5,246,500 72.0M USD −0.7% reduced Q3 2023 3 quarters
USB U.S. Bancorp 3.8% 22,626,465 1.0B USD +136.4% increased Q4 2023 2 quarters
TMUS T-Mobile US 2.7% 4,381,297 715.1M USD +190.2% increased Q4 2023 2 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Show more (up to 500) Shown: the 50 longest-held of 83 positions.

Breakdown by sector

  • Financials 17.3%
  • Technology 14.1%
  • Health Care 9.8%
  • Consumer Discretionary 7.9%
  • Consumer Staples 6.5%
  • Industrials 5.7%
  • Communication Services 5.1%
  • Materials 2.3%
  • Real Estate 2.0%
  • not in our coverage 29.3%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close